news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.
read more

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.
read more

RetinAI’s AI Algorithms Enrich Clinical Research and Improve Patient Care

RetinAI Medical AG has announced the acceptance of five abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) conference taking place from April 23rd to 26th, 2023 in New Orleans. These studies highlight the potential of RetinAI’s Discovery platform and its certified and research use only (RUO) AI models to revolutionize healthcare decisions, improve patient care, help accelerate clinical trials, and drive better decisions for patient management.
read more

RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients. 
read more

Latest updates

Swiss AI Day: Empower your business [JUNE'17]

RetinAI will be participating in the Swiss AI Day: EmPOWER your Business, taking place on June 14th in Bern, and featuring top speakers in finance, insurance, healthcare, life sciences and research in AI. Don't miss the date and register now!

Ready for MICCA! [MAY'17]

RetinAI + UniBern's collaboration on Optical Coherence Tomography (OCT) has outcome in a publication in the prestigious conference MICCAI'2017. Meet the RetinAI team in Quebec this September and have some discussions about Machine Learning in Ophthalmology.

‍

ARVO 2017, Baltimore [MAY'17]

Our team members travelled to the American Research in Vision and Ophthalmology (ARVO) conference 2017, in Baltimore, to present their products in the field of OCT image analysis and Fundus Imaging.

Contact us for more informations! We are happy to hear from you!

Contact Us

Ikerian AG (HQ)
‍Freiburgstrasse 3
3010 Bern
Switzerland
‍

RetinAI US Inc. (US)
6 Liberty Square
#2498 Boston, MA 02109
United States

Certifications
SolutionS For
Life Sciences & Pharma
Clinics & Hospitals
Device Manufacturers
Products
DISCOVERY
- UNITY
- For Clinical Studies
- For Clinics
REAL WORLD EVIDENCE
APPS FOR CLINICS
PRECISION MEDICINE
Contact
info@retinai.com
Media kit
Careers
Product User Manual

Imprint/Legal Notice  |  Data Processing Agreement  |  Privacy Notice  |  Created by Ikerian AG. All rights reserved 2016-2023 ©